<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213261</url>
  </required_header>
  <id_info>
    <org_study_id>FI-EB-002</org_study_id>
    <secondary_id>R01-7289-01</secondary_id>
    <nct_id>NCT04213261</nct_id>
  </id_info>
  <brief_title>A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa</brief_title>
  <acronym>DEFI-RDEB</acronym>
  <official_title>A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Castle Creek Biosciences, LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Castle Creek Biosciences, LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether administration of FCX-007 in addition to&#xD;
      standard of care improves wound healing as compared to standard of care alone (control) in&#xD;
      children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa.&#xD;
&#xD;
      Funding Source - FDA OOPD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DEFI-RDEB is a multi-center, intra-patient randomized, controlled, open-label, Phase 3 study&#xD;
      of FCX-007 for the treatment of persistent non-healing and recurrent RDEB wounds in&#xD;
      approximately 24 subjects. Each subject will serve as his/her own control. Each subject's&#xD;
      target wounds will be paired then randomized to receive FCX-007 (treatment wound) or remain&#xD;
      untreated (control wound). Up to three target wound pairs will be identified for each&#xD;
      subject.&#xD;
&#xD;
      Subjects will receive intradermal injections of FCX-007 in each specified treatment wound in&#xD;
      two or more treatment sessions. The first treatment session occurs at Day 1 and the second at&#xD;
      Week 12/Month 3. Additional treatment sessions may occur at Week 24/Month 6 and Week 36/Month&#xD;
      9 when unclosed treatment wounds may be re-treated, and unclosed control wounds may be&#xD;
      treated. Safety and efficacy assessments will occur at scheduled intervals through Week&#xD;
      48/Month 12, when the treatment period is completed, and a long-term safety follow-up period&#xD;
      (through 15 years) commences for subjects who have received one or more FCX-007 injections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Anticipated">July 2036</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Intra-patient Randomized, Controlled, Open-label, Multi-center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete wound closure of the First Wound Pair at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Complete wound closure of the first wound pair (treated vs. control)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete wound closure of the First Wound Pair at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Complete wound closure of first wound pair (treated vs. control)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete wound closure of all wound pairs at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Complete wound closure of all wound pairs (treated vs. control)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete wound closure of all wound pairs at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Complete wound closure of all wound pairs (treated vs. control)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Recessive Dystrophic Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>FCX-007 COL7A1 Genetically-Corrected Autologous Fibroblasts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-subject randomized (paired wounds in each subject receive experimental treatment, FCX-007, or remain untreated). Up to three target wound pairs will be identified for each subject. Following pairing, target wounds will be randomly assigned as the treatment wound (FCX-007 is administered) or control wound. Subjects will receive intradermal injections of FCX-007 in each specified treatment wound in two or more treatment sessions. The first treatment session occurs at Day 1 and the second at Week 12/Month 3. Additional treatment sessions may occur at Week 24/Month 6 and Week 36/Month 9 when unclosed treatment wounds may be re-treated, and unclosed control wounds may be treated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FCX-007 (dabocemagene autoficel; see below for FCX-007 description)</intervention_name>
    <description>FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.</description>
    <arm_group_label>FCX-007 COL7A1 Genetically-Corrected Autologous Fibroblasts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female â‰¥2 years of age at the Screening visit.&#xD;
&#xD;
          -  Clinical diagnosis of RDEB with confirmation of COL7A1 genetic mutation.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Medical instability limiting ability to travel to the investigative site.&#xD;
&#xD;
          -  Active infection with human immunodeficiency virus, hepatitis B or hepatitis C.&#xD;
&#xD;
          -  The presence of COL7 antibodies.&#xD;
&#xD;
          -  Evidence of systemic infection.&#xD;
&#xD;
          -  Evidence or history of squamous cell carcinoma at the site to be injected.&#xD;
&#xD;
          -  Evidence of or history of metastatic squamous cell carcinoma.&#xD;
&#xD;
          -  Known allergy to any of the constituents of the product.&#xD;
&#xD;
          -  Female who is pregnant or breastfeeding.&#xD;
&#xD;
          -  Receipt of a chemical or biological intervention for the specific treatment of RDEB in&#xD;
             the past three (3) months prior to screening or anticipated/planned during the&#xD;
             screening and treatment period for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunju J Sridhar, PhD</last_name>
      <phone>650-721-4902</phone>
      <email>kunju@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Marinkovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Peoples</last_name>
      <phone>720-777-4708</phone>
      <email>kathleen.peoples@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Anna Bruckner, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Solutions Through Advanced Research, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Thomas</last_name>
      <phone>904-619-8157</phone>
      <phone_ext>2</phone_ext>
      <email>Lisa.thomas@jaxadvresearch.com</email>
    </contact>
    <investigator>
      <last_name>Pearl Kwong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlin Schwartz</last_name>
      <phone>507-293-9114</phone>
      <email>schwartz.kaitlin@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Hand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Group</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan O'Neill, RN, BSN</last_name>
      <phone>512-324-9999</phone>
      <phone_ext>87905</phone_ext>
      <email>meghan.oneill@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Moise Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RDEB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

